Sanofi highlights positive PhIII study for myelofibrosis contender
The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become enlarged as a result of abnormal blood cell production.
Which Big Biotechs are hitting the gas pedal on R&D spending?The R&D numbers for the top 10 biotechs may only amount to a fraction of what you'll find in Big Pharma. But unlike the giants, which are trying to keep a lid on multibillion-dollar budgets, you'll find a much faster crowd when you turn your gaze to the biotechs. All 10 reported increases in their research spending for last year. And a few of them slammed their foot on the gas pedal.
Altogether the top 10 biotechs spent $11.8 billion on R&D in 2012, according to our research, a hefty 15% average increase over their 2011 performance. Compare that to the stable year-over-year record in Big Pharma, where doing more with the same amount of cash has become an industry mantra.
Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups
Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands. Termeer, the former chairman and CEO of Genzyme, left the biotech two months after Sanofi acquired it for more than $20 billion in April 2011 to seize control of its lucrative drugs for rare diseases. He was expected to stay involved in biotech, having engineered the growth of Genzyme from a small venture in the early 1980s to a multibillion-dollar force in the industry. Yet not even he could have predicted all the new companies and entrepreneurs he would add to his professional circle.VC questions thinking of Obama's BRAIN initiative
At the risk of looking a gift horse in the mouth, or more precisely two gift horses, I would like to reconsider the BRAIN initiative that President Obama announced as part of the budget package he sent to Congress on April 2. I am all for initiative. I am no fan of big government, but government-sponsored large-scale basic research works. In fact it is essential if we are to provide healthcare to a country with an aging population, a shrinking workforce and a growing burden of chronic disease. The task is daunting at best and, without new insights and therapeutic tools, virtually impossible.
TOP HEADLINES
Featured Story
UPDATED: PTC, Esperion, bluebird join the IPO frenzy in biotech with genetic therapies
Two more biotech outfits emerged this week as contenders to complete initial public offerings, highlighting the open season for the deals this year. Bluebird bio and PTC Therapeutics has mounted campaigns to go public with pipelines that target the molecular causes of rare genetic diseases.
Evotec, Harvard partner up to develop new antibacterials
More biotech companies are forging academic partnerships as they downsize their internal R&D efforts, and another outfit to ride that wave is Germany's Evotec AG. Evotec will collaborate with Harvard University to hunt for and develop new anti-bacterial agents and advance them toward the clinic.
Sanofi balks on jobs promises at R&D site in Toulouse
Sanofi can't shake the underproductive R&D site in Toulouse, France, without a fight from workers and French government officials. In the latest chapter of the ongoing feud, the Paris-based drug giant and a familiar critic in France's government show how far apart they stand on the fate of the research operation that brought the world the blood-thinner
AbbVie, Galapagos extend JAK1 pact into Crohn's disease with $50M carrot
The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.
Novo Nordisk completes PhIII hemophilia trial with positive results
In a Friday announcement, Novo Nordisk said it completed the first phase III trial of its drug N9-GP for hemophilia B patients.
Bristol-Myers edges ahead in race to develop first blockbuster PD-1 cancer drug
Bristol-Myers Squibb has emerged, at least temporarily, as the leader in a race to develop the first new PD-1 drug to fight cancer.
From Our Sister Sites
A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation.
Vascular Solutions is suing Boston Scientific, claiming the company's Guidezilla extension catheter infringes on its patents and asking a Minnesota court to hault the device's sale.
POPULAR COMMENT THREADS